1 terminated. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
Follow PF-07284890: new trials by email Literature Review of PF-07284890 trials Research Report on PF-07284890
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement PF-07284890, Binimetinib, Midazolam - Malignant Melanoma, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Pfizer | 65 | 2021-01-08 | 2025-10-23 |
Brain Diseases (1) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Central Nervous System Neoplasms (1) · Melanoma (1) · Neoplasms (1)
Pfizer (1)
Canada (1) · Israel (1) · United States (1)